Bacteremia – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033
Bacteremia, strictly defined, denotes the presence of viable bacteria within the bloodstream. Asymptomatic bacteremia can arise from everyday activities like oral hygiene or minor medical procedures. These seemingly harmless infections are brief in healthy individuals and don't lead to further complications. However, if the body's immune response falters or gets overwhelmed, bacteremia can become a bloodstream infection, encompassing various clinical scenarios, and is termed septicemia. When untreated and significant, bacteremia advances to systemic inflammatory response syndrome (SIRS), sepsis, septic shock, and multiple organ dysfunction syndrome (MODS). Among hospitalized patients, common sources include the respiratory tract and indwelling catheters, particularly central venous catheters. Community-acquired bacteremia often results from untreated urinary tract infections. While less frequent, soft tissue and intraabdominal infections are more prevalent after surgical procedures. Gram-negative bacteremia is predominantly caused by Escherichia coli, while gram-positive bacteremia is most commonly attributed to Staphylococcus aureus. The success of bacterial infections hinges on the host's immune system, influenced by genetic traits, congenital factors, and acquired deficiencies. Initial clearance of microbes relies on cellular innate and adaptive immune responses, while the liver and spleen filter active bacteria in the bloodstream. Typically, bacteria establish themselves at their primary site of origin. They can either remain transient and medically inconsequential or evade the immune system, multiplying to form a localized infection that might spread elsewhere in the body. If viable bacteria enter the bloodstream, the infection could resolve spontaneously or escalate to septicemia. The skin and mucosal surfaces serve as the first line of defense against bacterial invasion. Interference with these natural barriers often arises from medical procedures that breach the skin or anatomical pathways. Additionally, events like trauma, burns, ulcers, and the aging process can compromise these defenses.
- The incidence of staphylococcus aureus bacteremia (SAB) spans 9.3 to 65 cases per 100,000 individuals annually. The median age of SAB patients ranges from 62 to 72 years, with a higher occurrence in men than women.
Thelansis’s “Bacteremia Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Bacteremia treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
KOLs insights of Bacteremia across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.
Bacteremia Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.
Comments
Post a Comment